TP53 mutation is a relatively early event during the development of an astrocytoma, whereas loss or mutation of PTEN and amplification of EGFR are characteristics of higher-grade tumors (Weber et al., 1996; Furnari et al., 2007; Ohgaki and Kleihues 2007). Here, EGFR is linked to astrocytoma (excluding glioblastoma).